We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE Collaborates with CBMG to Enhance Healthcare Portfolio
Read MoreHide Full Article
General Electric Company (GE - Free Report) recently collaborated with a leading clinical-stage biopharmaceutical firm, Cellular Biomedicine Group Inc. to co-develop certain high-quality industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing.
Cellular Biomedicine develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The company conducts immuno-oncology and stem cell clinical trials in China, integrating products from its GMP laboratory. At the GMP facilities in China, the company comprises 12 independent cell production lines, which are designed and managed according to both China and U.S. GMP standards.
Per the collaboration, a joint laboratory within Cellular Biomedicine’s new Shanghai Zhangjiang GMP facility will be set up to research and develop a functionally integrated and automated immunotherapy cell preparation system. This will help standardize the delivery of cell manufacturing to augment output, reduce cost burdens and inconsistency in cell production, which in turn is likely to increase the availability of engineered cells upon commercialization.
On combining Cellular Biomedicine's expertise of CAR-T and stem cell production and GE Healthcare's expertise in the design and development of innovative manufacturing technologies for the biopharmaceutical industry, customers will get access to best in class solutions.
The Cell therapy as an industry continues to refine and evolve in China as it tries to change the ways various diseases are treated. General Electric continues to invest in technologies and services that aim at making these therapies accessible to people. This collaboration will enable it to further enhance its foothold in the healthcare industry.
Continuous initiatives to augment product offerings and strengthen its foothold helped General Electric to outperform the Zacks categorized Diversified Operations industry over the last 30 days. It recorded an average gain of 0.5% against 0.2% decline of the industry.
3M has a long-term earnings growth expectation of 9.7%. The company beat earnings estimates thrice in the trailing four quarters with an average positive surprise of 1.9%.
Bunzl has a long-term earnings growth expectation of 7.5% and is currently trading at a forward P/E of 20.4x.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GE Collaborates with CBMG to Enhance Healthcare Portfolio
General Electric Company (GE - Free Report) recently collaborated with a leading clinical-stage biopharmaceutical firm, Cellular Biomedicine Group Inc. to co-develop certain high-quality industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing.
Cellular Biomedicine develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The company conducts immuno-oncology and stem cell clinical trials in China, integrating products from its GMP laboratory. At the GMP facilities in China, the company comprises 12 independent cell production lines, which are designed and managed according to both China and U.S. GMP standards.
Per the collaboration, a joint laboratory within Cellular Biomedicine’s new Shanghai Zhangjiang GMP facility will be set up to research and develop a functionally integrated and automated immunotherapy cell preparation system. This will help standardize the delivery of cell manufacturing to augment output, reduce cost burdens and inconsistency in cell production, which in turn is likely to increase the availability of engineered cells upon commercialization.
On combining Cellular Biomedicine's expertise of CAR-T and stem cell production and GE Healthcare's expertise in the design and development of innovative manufacturing technologies for the biopharmaceutical industry, customers will get access to best in class solutions.
The Cell therapy as an industry continues to refine and evolve in China as it tries to change the ways various diseases are treated. General Electric continues to invest in technologies and services that aim at making these therapies accessible to people. This collaboration will enable it to further enhance its foothold in the healthcare industry.
Continuous initiatives to augment product offerings and strengthen its foothold helped General Electric to outperform the Zacks categorized Diversified Operations industry over the last 30 days. It recorded an average gain of 0.5% against 0.2% decline of the industry.
General Electric currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the industry include 3M Company (MMM - Free Report) and Bunzl plc (BZLFY - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
3M has a long-term earnings growth expectation of 9.7%. The company beat earnings estimates thrice in the trailing four quarters with an average positive surprise of 1.9%.
Bunzl has a long-term earnings growth expectation of 7.5% and is currently trading at a forward P/E of 20.4x.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>